In a surprising move, Sutro Biopharma has decided to undertake a sweeping restructuring plan with the primary goal of conserving capital, leading to a nearly 50% reduction in its workforce, the ousting of CEO Bill Newell, the discontinuation of its lead drug candidate luveltamab tazevibulin
Ivan Kairatov is a Biopharma expert, with deep knowledge of tech and innovation in the industry and experience in research and development. Today, we will be discussing the Medicines Manufacturing Centre (MMC) project in the U.K., the increasing demand for monoclonal antibodies (mAbs) and advanced
The single-use bioprocessing connectors market is witnessing an unprecedented surge, revolutionizing the realm of biopharmaceutical production across the globe. This article delves into the multifaceted dynamics driving this market growth, exploring its crucial segments, regional variations, and
The Europe medical gloves market, valued at USD 4.35 billion in 2024, is set to grow steadily, reaching USD 7.89 billion by 2033. As healthcare demands rise, so does the reliance on medical gloves—a critical component in infection control. However, environmental concerns loom large over this b
As the landscape of biopharmaceutical manufacturing undergoes significant changes, Danaher Corporation stands at a pivotal crossroads with the potential to lead through its innovative strategies and products. At the TD Cowen Health Care Conference, Danaher President and CEO Rainer Blair emphasized
Repligen, an innovative leader in bioprocess technology, has made a strategic move by acquiring essential upstream Process Analytical Technology (PAT) assets from 908 Devices for a total of $70 million. This acquisition should be viewed as more than just a simple addition of technology; it
